0001493152-24-010733.txt : 20240321 0001493152-24-010733.hdr.sgml : 20240321 20240321083025 ACCESSION NUMBER: 0001493152-24-010733 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240320 FILED AS OF DATE: 20240321 DATE AS OF CHANGE: 20240321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Larson Douglas Quinton CENTRAL INDEX KEY: 0001880132 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38892 FILM NUMBER: 24769575 MAIL ADDRESS: STREET 1: BEYOND AIR, INC. STREET 2: 900 STEWART AVENUE, SUITE 301 CITY: GARDEN CITY STATE: NY ZIP: 11530 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Beyond Air, Inc. CENTRAL INDEX KEY: 0001641631 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 473812456 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 900 STEWART AVENUE STREET 2: SUITE 301 CITY: GARDEN CITY STATE: NY ZIP: 11530 BUSINESS PHONE: 516-665-8200 MAIL ADDRESS: STREET 1: 900 STEWART AVENUE STREET 2: SUITE 301 CITY: GARDEN CITY STATE: NY ZIP: 11530 FORMER COMPANY: FORMER CONFORMED NAME: AIT Therapeutics, Inc. DATE OF NAME CHANGE: 20170117 FORMER COMPANY: FORMER CONFORMED NAME: KokiCare, Inc. DATE OF NAME CHANGE: 20150507 4 1 ownership.xml X0508 4 2024-03-20 0 0001641631 Beyond Air, Inc. XAIR 0001880132 Larson Douglas Quinton C/O BEYOND AIR, INC. 900 STEWART AVENUE, SUITE 301 GARDEN CITY NY 11530 0 1 0 0 Chief Financial Officer 0 Common Stock 2024-03-20 4 A 0 12048 1.66 A 27548 D Warrants (right to buy) 2.25 2024-03-20 4 A 0 12048 0 A 2024-03-22 2027-03-22 Common Stock 12048 12048 D Represents the common stock of Beyond Air, Inc. acquired by the reporting person in a registered direct offering on March 20, 2024, at a price of $1.66 per share. Represents the warrants of Beyond Air, Inc. acquired by the reporting person in a registered direct offering on March 20, 2024. The warrants will be exercisable immediately upon issuance, at an exercise price of $2.25 per share and will have a term of three years following the date of issuance. /s/ Douglas Quinton Larson 2024-03-21